Giuseppe Toffoli
Overview
Explore the profile of Giuseppe Toffoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
3227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Mattia E, Milan N, Assaraf Y, Toffoli G, Cecchin E
Int J Biol Sci
. 2024 Aug;
20(10):3742-3759.
PMID: 39113696
Fluoropyrimidines (FLs) [5-Fluorouracil, Capecitabine] are used in the treatment of several solid tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for FL detoxification, and its deficiency could lead to severe,...
12.
Riccardi F, Tangredi C, Dal Bo M, Toffoli G
Front Oncol
. 2024 Apr;
14:1370854.
PMID: 38655136
Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined...
13.
Posocco B, Zanchetta M, Orleni M, Gagno S, Montico M, Peruzzi E, et al.
Ther Drug Monit
. 2024 Feb;
46(4):485-493.
PMID: 38366332
Background: Therapeutic drug monitoring (TDM) using cyclin-dependent kinase inhibitors (CDK4/6is) is a novel approach for optimizing treatment outcomes. Currently, palbociclib, ribociclib, and abemaciclib are the available CDK4/6is and are primarily...
14.
Mondello A, Dal Bo M, Toffoli G, Polano M
Front Pharmacol
. 2024 Jan;
14:1260276.
PMID: 38264526
Over the past two decades, Next-Generation Sequencing (NGS) has revolutionized the approach to cancer research. Applications of NGS include the identification of tumor specific alterations that can influence tumor pathobiology...
15.
Gambirasi M, Safa A, Vruzhaj I, Giacomin A, Sartor F, Toffoli G
Vaccines (Basel)
. 2024 Jan;
12(1).
PMID: 38250839
Cancer vaccines, a burgeoning strategy in cancer treatment, are exploring innovative administration routes to enhance patient and medical staff experiences, as well as immunological outcomes. Among these, oral administration has...
16.
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
Vianello C, Cocetta V, Catanzaro D, Dorn 2nd G, De Milito A, Rizzolio F, et al.
Cell Death Dis
. 2024 Jan;
15(1):68.
PMID: 38238295
No abstract available.
17.
Busato D, Capolla S, Durigutto P, Mossenta M, Bozzer S, Sblattero D, et al.
J Transl Med
. 2023 Nov;
21(1):864.
PMID: 38017492
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest...
18.
Gagno S, Dalle Fratte C, Posocco B, Buonadonna A, Fumagalli A, Guardascione M, et al.
Pharmacogenomics
. 2023 Nov;
24(18):895-900.
PMID: 37955064
Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to...
19.
De Mattia E, Polesel J, Silvestri M, Roncato R, Scarabel L, Calza S, et al.
Hum Genomics
. 2023 Nov;
17(1):99.
PMID: 37946254
Background: Despite a growing number of publications highlighting the potential impact on the therapy outcome, rare genetic variants (minor allele frequency < 1%) in genes associated to drug adsorption, distribution,...
20.
Peruzzi E, Roncato R, De Mattia E, Bignucolo A, Swen J, Guchelaar H, et al.
Br J Clin Pharmacol
. 2023 Nov;
91(2):270-282.
PMID: 37926674
Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among adults and are more common in multimorbid patients, worsening clinical outcomes and burdening healthcare resources. Over the past...